Mandate

Vinge advises Scandinavian Office Group in acquisition of Kontorsvaruhuset

February 21, 2013

Vinge is advising Scandinavian Office Group in connection with the acquisition of Kontorsvaruhuset. Litorina is the majority shareholder in Scandinavian Office Group, which has been owned by Gullbergs since the summer of 2012. Kontorsvaruhuset Gullbergs has been formed as a result of a merger between Gullbergs and Kontorsvaruhuset. The new group will be one of Sweden’s leading suppliers of office supplies and consumable materials as well as related services to both the private sector and public sector. The new group will have nationwide coverage, a turnover of approximately SEK 1.1 billion and have approximately 500 employees. The acquisition is subject to the approval of the Swedish Competition Authority.

Vinge’s team assisting the buyer consists of responsible partner Johan Winnerblad together with, among others, associates Kristina Ekberg and Louise Markgren. Partner Johan Karlsson and associate Peter Alstergren are providing competition law advice.

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025